Inflammatory-Targeted Lipid Carrier as a New Nanomaterial to Formulate an Inhaled Drug Delivery System
Laboratory studyOther animals
- Design
- Laboratory study
- Subjects
- MH-S mouse alveolar macrophage cell line; no animals or people
- Dose used in the study
- Lipid nanoparticles made from palmitoylethanolamide, tested on cells up to 0.64 mg/mL
- Duration
- Not stated in the abstract
- What was measured
- Particle size and shape, PEA solubility, aerosol performance of freeze-dried powders, cell toxicity and uptake by macrophages.
What the authors reported
The study found:
- PEA nanoparticles were about 250 nm, rounded, and much more soluble than raw PEA.
- More mannose as cryoprotectant improved the emitted dose and fine particle fraction in an aerosol test.
- The particles were not toxic to MH-S macrophages up to 0.64 mg/mL and were taken up rapidly by the cells.
Limits of this study
A formulation and cell study only; it cannot show effect in people or animals. No inhaled dosing in a living organism and no disease model. The authors declare no conflicts of interest.
Source
PubMed 38611895 · doi:10.3390/molecules29071616
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.